Nasser, Azmi
Hull, Joseph T.
Chaturvedi, Soumya A.
Liranso, Tesfaye
Odebo, Oyinkansola
Kosheleff, Alisa R.
Fry, Nicholas
Cutler, Andrew J.
Rubin, Jonathan
Schwabe, Stefan
Childress, Ann
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
https://doi.org/10.1007/s40263-022-00938-w
Article History
Accepted: 6 July 2022
First Online: 27 July 2022
Declarations
:
: This research was entirely supported by Supernus Pharmaceuticals, Inc. Open access publication was funded by Supernus Pharmaceuticals, Inc.
: AN, JTH, TL, NF, and JR, are employees of Supernus Pharmaceuticals, Inc. SAC, OO, ARK, and SS were employees of Supernus Pharmaceuticals, Inc. at the time of this work. AJC has received research support from Aevi Genomics, Akili Interactive, Arbor Pharmaceuticals, Ironshore Pharmaceuticals, Janssen, KemPharm, Lundbeck, Neos Therapeutics (now Aytu BioPharma), Neurovance, Noven, Otsuka, Purdue Canada, Rhodes Pharmaceuticals, Shire, Sunovion, Supernus Pharmaceuticals, Inc., Takeda, and Tris Pharma. He has received fees for consulting, advisory boards, and promotional speaking from Adlon Therapeutics, Aevi Genomics, Akili Interactive, Arbor Pharmaceuticals, Atentiv, Cingulate Therapeutics, Corium, Ironshore Pharmaceuticals, Janssen, Lundbeck, MedAvante-ProPhase, Neos Therapeutics (now Aytu BioPharma), NLS Pharmaceutics, Noven, Otsuka, Shire, Sunovion, Supernus Pharmaceuticals, Inc., Takeda, and Tris Pharma. He is an employee and board member of the Neuroscience Education Institute. AC has received research support from, served as a consultant or speaker for, or served on an advisory board for Allergan, Takeda (Shire), Emalex, Pearson, Akili, Arbor, Cingulate Therapeutics, Ironshore, Lumos, Aevi Genomic Medicine, Neos Therapeutics, Neurovance, Noven, Otsuka, Pfizer, Purdue, Adlon, Rhodes, Sunovion, Tris, KemPharm, Supernus Pharmaceuticals, Inc., US Food and Drug Administration, NLS Pharma, and Jazz.
: The study was approved by the WIRB-Copernicus Group Institutional Review Board and conducted in accordance with the Helsinki Declaration and the International Council for Harmonisation Good Clinical Practice Guidelines.
: Each subject provided written informed consent prior to screening.
: Not applicable.
: The data are not available in a repository, but requests can be directed to anasser@supernus.com.
: Not applicable.
: Conceptualization and design: AN, JTH, TL, OO, SAC, SS. Methodology and data collection: AN, JTH, TL, OO, NF, AJC, SS, AC. Analysis and interpretation: AN, JTH, TL, OO, SAC, SS, JR. Writing, original draft preparation: AN, JTH, SAC, ARK. Writing, review and editing: AN, JTH, SAC, ARK, AJC, JR, AC. All authors have read and approve the final submitted manuscript and agree to be accountable for this work.